BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 31199475)

  • 1. White matter hyperintensities: relationship to amyloid and tau burden.
    Graff-Radford J; Arenaza-Urquijo EM; Knopman DS; Schwarz CG; Brown RD; Rabinstein AA; Gunter JL; Senjem ML; Przybelski SA; Lesnick T; Ward C; Mielke MM; Lowe VJ; Petersen RC; Kremers WK; Kantarci K; Jack CR; Vemuri P
    Brain; 2019 Aug; 142(8):2483-2491. PubMed ID: 31199475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions.
    Weaver NA; Doeven T; Barkhof F; Biesbroek JM; Groeneveld ON; Kuijf HJ; Prins ND; Scheltens P; Teunissen CE; van der Flier WM; Biessels GJ;
    Neurobiol Aging; 2019 Dec; 84():225-234. PubMed ID: 31500909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma soluble TREM2 is associated with white matter lesions independent of amyloid and tau.
    Tsai HH; Chen YF; Yen RF; Lo YL; Yang KC; Jeng JS; Tsai LK; Chang CF
    Brain; 2021 Dec; 144(11):3371-3380. PubMed ID: 34515756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRI-visible perivascular space location is associated with Alzheimer's disease independently of amyloid burden.
    Banerjee G; Kim HJ; Fox Z; Jäger HR; Wilson D; Charidimou A; Na HK; Na DL; Seo SW; Werring DJ
    Brain; 2017 Apr; 140(4):1107-1116. PubMed ID: 28335021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. White matter hyperintensities are higher among early-onset Alzheimer's disease participants than their cognitively normal and early-onset nonAD peers: Longitudinal Early-onset Alzheimer's Disease Study (LEADS).
    Eloyan A; Thangarajah M; An N; Borowski BJ; Reddy AL; Aisen P; Dage JL; Foroud T; Ghetti B; Griffin P; Hammers D; Iaccarino L; Jack CR; Kirby K; Kramer J; Koeppe R; Kukull WA; La Joie R; Mundada NS; Murray ME; Nudelman K; Rumbaugh M; Soleimani-Meigooni DN; Toga A; Touroutoglou A; Atri A; Day GS; Duara R; Graff-Radford NR; Honig LS; Jones DT; Masdeu J; Mendez MF; Musiek E; Onyike CU; Rogalski E; Salloway S; Sha S; Turner RS; Wingo TS; Wolk DA; Womack K; Beckett L; Gao S; Carrillo MC; Rabinovici G; Apostolova LG; Dickerson B; Vemuri P;
    Alzheimers Dement; 2023 Nov; 19 Suppl 9(Suppl 9):S89-S97. PubMed ID: 37491599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extravascular fibrinogen in the white matter of Alzheimer's disease and normal aged brains: implications for fibrinogen as a biomarker for Alzheimer's disease.
    McAleese KE; Graham S; Dey M; Walker L; Erskine D; Johnson M; Johnston E; Thomas AJ; McKeith IG; DeCarli C; Attems J
    Brain Pathol; 2019 May; 29(3):414-424. PubMed ID: 30485582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association between white matter hyperintensities and amyloid and tau deposition.
    Alban SL; Lynch KM; Ringman JM; Toga AW; Chui HC; Sepehrband F; Choupan J;
    Neuroimage Clin; 2023; 38():103383. PubMed ID: 36965457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topographic patterns of white matter hyperintensities are associated with multimodal neuroimaging biomarkers of Alzheimer's disease.
    Gaubert M; Lange C; Garnier-Crussard A; Köbe T; Bougacha S; Gonneaud J; de Flores R; Tomadesso C; Mézenge F; Landeau B; de la Sayette V; Chételat G; Wirth M
    Alzheimers Res Ther; 2021 Jan; 13(1):29. PubMed ID: 33461618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No neuropathological evidence for a direct topographical relation between microbleeds and cerebral amyloid angiopathy.
    Kövari E; Charidimou A; Herrmann FR; Giannakopoulos P; Bouras C; Gold G
    Acta Neuropathol Commun; 2015 Aug; 3():49. PubMed ID: 26268348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions between vascular burden and amyloid-β pathology on trajectories of tau accumulation.
    Coomans EM; van Westen D; Binette AP; Strandberg O; Spotorno N; Serrano GE; Beach TG; Palmqvist S; Stomrud E; Ossenkoppele R; Hansson O
    Brain; 2024 Mar; 147(3):949-960. PubMed ID: 37721482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Data-Driven White Matter Hyperintensity Spatial Signatures With Distinct Cerebral Small Vessel Disease Etiologies.
    Phuah CL; Chen Y; Strain JF; Yechoor N; Laurido-Soto OJ; Ances BM; Lee JM;
    Neurology; 2022 Dec; 99(23):e2535-e2547. PubMed ID: 36123127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebral Microhemorrhage at MRI in Mild Cognitive Impairment and Early Alzheimer Disease: Association with Tau and Amyloid β at PET Imaging.
    Rauchmann BS; Ghaseminejad F; Mekala S; Perneczky R;
    Radiology; 2020 Jul; 296(1):134-142. PubMed ID: 32368960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebral microbleeds topography and cerebrospinal fluid biomarkers in cognitive impairment.
    Shams S; Granberg T; Martola J; Charidimou A; Li X; Shams M; Fereshtehnejad SM; Cavallin L; Aspelin P; Wiberg-Kristoffersen M; Wahlund LO
    J Cereb Blood Flow Metab; 2017 Mar; 37(3):1006-1013. PubMed ID: 27178426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of cerebrospinal fluid profiles in Alzheimer's disease with multiple cerebral microbleeds and cerebral amyloid angiopathy-related inflammation.
    Kimura A; Takemura M; Saito K; Yoshikura N; Hayashi Y; Harada N; Nishida H; Nakajima H; Inuzuka T
    J Neurol; 2017 Feb; 264(2):373-381. PubMed ID: 28000005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of common reference regions on regional tau patterns in cross-sectional and longitudinal [
    Young CB; Landau SM; Harrison TM; Poston KL; Mormino EC;
    Neuroimage; 2021 Nov; 243():118553. PubMed ID: 34487825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal Fluid, MRI, and Florbetaben-PET in Cerebral Amyloid Angiopathy-Related Inflammation.
    Renard D; Collombier L; Demattei C; Wacongne A; Charif M; Ayrignac X; Azakri S; Gaillard N; Boudousq V; Lehmann S; Menjot de Champfleur N; Thouvenot E
    J Alzheimers Dis; 2018; 61(3):1107-1117. PubMed ID: 29254099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between brain amyloid deposition and longitudinal changes of white matter hyperintensities.
    Cha WJ; Yi D; Ahn H; Byun MS; Chang YY; Choi JM; Kim K; Choi H; Jung G; Kang KM; Sohn CH; Lee YS; Kim YK; Lee DY
    Alzheimers Res Ther; 2024 Mar; 16(1):50. PubMed ID: 38454444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
    Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
    Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain Amyloid PET Tracer Delivery is Related to White Matter Integrity in Patients with Mild Cognitive Impairment.
    Brown EE; Rashidi-Ranjbar N; Caravaggio F; Gerretsen P; Pollock BG; Mulsant BH; Rajji TK; Fischer CE; Flint A; Mah L; Herrmann N; Bowie CR; Voineskos AN; Graff-Guerrero A;
    J Neuroimaging; 2019 Nov; 29(6):721-729. PubMed ID: 31270885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer's disease.
    Lee S; Zimmerman ME; Narkhede A; Nasrabady SE; Tosto G; Meier IB; Benzinger TLS; Marcus DS; Fagan AM; Fox NC; Cairns NJ; Holtzman DM; Buckles V; Ghetti B; McDade E; Martins RN; Saykin AJ; Masters CL; Ringman JM; Fӧrster S; Schofield PR; Sperling RA; Johnson KA; Chhatwal JP; Salloway S; Correia S; Jack CR; Weiner M; Bateman RJ; Morris JC; Mayeux R; Brickman AM;
    PLoS One; 2018; 13(5):e0195838. PubMed ID: 29742105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.